LB Pharmaceuticals (LBRX)
Develops LB-102 for schizophrenia, bipolar depression, and related neuropsychiatric disorders.
$51.00
Pre-market+1.56 (+3.16%)
At close$49.44(+4.97%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
estimated · in 63 days
EPS estimate
−$1.61
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
———Nov '25Mar '26May '26Aug '26Nov '26
Reported———−$0.61−$0.45−$0.67−$1.71Pending
Estimate———−$0.57−$0.45−$0.75−$0.80−$1.61
Surprise———−7.0%0.0%+10.7%−112.8%—
RevenueReportedEstimate
———Nov '25Mar '26May '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$1.61 | — | — |
| Aug 2026 | −$0.80 | −$1.71 | −112.8% |
| Jun 2026 | −$0.78 | — | — |
| May 2026 | −$0.75 | −$0.67 | +10.7% |
| Mar 2026 | −$0.45 | −$0.45 | 0.0% |
| Nov 2025 | −$0.57 | −$0.61 | −7.0% |
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$1.61 | — | — | — | — | — | — |
| Aug 11, 2026 | −$0.80 | −$1.71 | −112.8% | — | — | — | −1.1% |
| Jun 25, 2026 | −$0.78 | — | — | — | — | — | — |
| May 12, 2026 | −$0.75 | −$0.67 | +10.7% | — | — | — | +3.8% |
| Mar 26, 2026 | −$0.45 | −$0.45 | 0.0% | — | — | — | −2.8% |
| Nov 6, 2025 | −$0.57 | −$0.61 | −7.0% | — | — | — | −1.0% |